

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 55130

Title: Long-term Remission after Chidamide Combined with Chemotherapy and Single-drug Maintenance Therapy in Hepatosplenic T-cell Lymphoma: A Case Report

Reviewer's code: 03271124

Position: Peer Reviewer

Academic degree: FRCS (Gen Surg), MD

Professional title: Assistant Professor, Surgeon

Reviewer's Country/Territory: Thailand

Author's Country/Territory: China

Manuscript submission date: 2020-03-14

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-03-15 12:15

Reviewer performed review: 2020-03-18 10:55

Review time: 2 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear author, The manuscript entitled “Long-term remission after Chidamide combined with chemotherapy and single-drug maintenance therapy in hepatosplenic T-cell lymphoma: a case report” is well written. Comments, 1. What is the median survival for the hepatosplenic T-cell lymphoma patient from previous reports? This data should show in the introduction part. 2. The data of the Chidamide should be briefly showed in the introduction part. 3. The author should show more data in the outcome and follow-up part. including, a. What is the management after lymphoma progression? b. How progression of the disease? c. What is the exact cause of death? According to the data, the patient died only one month after disease progression from about 9 months of remission. This time interval seemed to be relatively short. Thus, is there any possibly occult disease in the nine months period?